IFNB1 and myeloid sarcoma: Interestingly, sVCAM-1 serum levels in MS patients not receiving IFN-β treatment were shown to positively correlate with the presence of Gd-enhancing lesions on brain MRI scans and with clinical disease activity in a majority of studies [15, 18, 19, 22, 36, 37].